BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28006839)

  • 1. High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.
    Bennett L; Quinn J; McCall P; Mallon EA; Horgan PG; McMillan DC; Paul A; Edwards J
    Int J Cancer; 2017 Apr; 140(7):1633-1644. PubMed ID: 28006839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between members of the canonical NF-κB pathway, components of tumour microenvironment and survival in patients with invasive ductal breast cancer.
    Bennett L; Mallon EA; Horgan PG; Paul A; McMillan DC; Edwards J
    Oncotarget; 2017 May; 8(20):33002-33013. PubMed ID: 28423692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.
    Kastrati I; Joosten SEP; Semina SE; Alejo LH; Brovkovych SD; Stender JD; Horlings HM; Kok M; Alarid ET; Greene GL; Linn SC; Zwart W; Frasor J
    Mol Cancer Res; 2020 Jul; 18(7):1018-1027. PubMed ID: 32245803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
    Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
    Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma.
    Rojo F; González-Pérez A; Furriol J; Nicolau MJ; Ferrer J; Burgués O; Sabbaghi M; González-Navarrete I; Cristobal I; Serrano L; Zazo S; Madoz J; Servitja S; Tusquets I; Albanell J; Lluch A; Rovira A; Eroles P
    Br J Cancer; 2016 Jul; 115(3):322-31. PubMed ID: 27404455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the prognostic significance of IKKα in prostate cancer.
    Montes M; MacKenzie L; McAllister MJ; Roseweir A; McCall P; Hatziieremia S; Underwood MA; Boyd M; Paul A; Plevin R; MacKay SP; Edwards J
    Prostate; 2020 Oct; 80(14):1188-1202. PubMed ID: 33258506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
    Yamaguchi N; Nakayama Y; Yamaguchi N
    J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.
    Lehn S; Tobin NP; Sims AH; Stål O; Jirström K; Axelson H; Landberg G
    BMC Cancer; 2014 Feb; 14():119. PubMed ID: 24559095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between oestrogen receptor-alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer.
    Cheng KK; Dickson A; Gujam FJ; McMillan DC; Edwards J
    Histopathology; 2017 Apr; 70(5):782-797. PubMed ID: 27891654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SIRT2: tumour suppressor or tumour promoter in operable breast cancer?
    McGlynn LM; Zino S; MacDonald AI; Curle J; Reilly JE; Mohammed ZM; McMillan DC; Mallon E; Payne AP; Edwards J; Shiels PG
    Eur J Cancer; 2014 Jan; 50(2):290-301. PubMed ID: 24183459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer.
    Johansson HJ; Sanchez BC; Mundt F; Forshed J; Kovacs A; Panizza E; Hultin-Rosenberg L; Lundgren B; Martens U; Máthé G; Yakhini Z; Helou K; Krawiec K; Kanter L; Hjerpe A; Stål O; Linderholm BK; Lehtiö J
    Nat Commun; 2013; 4():2175. PubMed ID: 23868472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.
    Hilborn E; Gacic J; Fornander T; Nordenskjöld B; Stål O; Jansson A
    Br J Cancer; 2016 Feb; 114(3):248-55. PubMed ID: 26742006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas.
    Bates GJ; Fox SB; Han C; Launchbury R; Leek RD; Harris AL; Banham AH
    Breast Cancer Res Treat; 2008 Oct; 111(3):453-9. PubMed ID: 18026833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro.
    Lanigan F; Gremel G; Hughes R; Brennan DJ; Martin F; Jirström K; Gallagher WM
    Breast Cancer Res; 2010; 12(4):R59. PubMed ID: 20682066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
    Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
    Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
    Bostner J; Skoog L; Fornander T; Nordenskjöld B; Stål O
    Clin Cancer Res; 2010 Mar; 16(5):1624-33. PubMed ID: 20179234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.